Breakthrough Therapy Designation
The FDA has granted Zogenix a Breakthrough Therapy Designation for its pipeline product, ZX008 for the treatment of seizures associated with Dravet syndrome.
Drug could get new indication based on NIH research
Patients suffering from a recurrent C diff infection have benefited from Rebiotix’s microbiome treatment.
Alecensa and Roactemra are breakthroughs, says FDA.
Drug could help prevent some of the 41,000 suicides every year in US
Janssen’s drug looking to gain bigger share in crowded myeloma market